Ngā hua rapu - Manosuthi, Weerawat

Whakamahine hua
  1. 1
    Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis

    Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis mā Manosuthi, Weerawat, Wiboonchutikul, Surasak

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Prevalence of Non-AIDS Comorbidities and Factors Associated with Metabolic Complications among HIV-Infected Patients at a Thai Referral Hospital

    Prevalence of Non-AIDS Comorbidities and Factors Associated with Metabolic Complications among HIV-Infected Patients at a Thai Referral Hospital mā Nakaranurack, Chotirat, Manosuthi, Weerawat

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Integrated therapy for HIV and tuberculosis

    Integrated therapy for HIV and tuberculosis mā Manosuthi, Weerawat, Wiboonchutikul, Surasak, Sungkanuparph, Somnuek

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Zero Transmission of Middle East Respiratory Syndrome: Lessons Learned From Thailand

    Zero Transmission of Middle East Respiratory Syndrome: Lessons Learned From Thailand mā Wiboonchutikul, Surasak, Manosuthi, Weerawat, Sangsajja, Chariya

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    A retrospective study of survival and risk factors for mortality among people living with HIV who received antiretroviral treatment in a resource-limited setting

    A retrospective study of survival and risk factors for mortality among people living with HIV who received antiretroviral treatment in a resource-limited setting mā Manosuthi, Weerawat, Charoenpong, Lantharita, Santiwarangkana, Chalor

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study

    Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study mā Manosuthi, Weerawat, Chumpathat, Nopphanath, Chaovavanich, Achara, Sungkanuparph, Somnuek

    I whakaputaina 2005
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm(3)

    Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD... mā Manosuthi, Weerawat, Chimsuntorn, Sukanya, Likanonsakul, Sirirat, Sungkanuparph, Somnuek

    I whakaputaina 2007
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole

    Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluco... mā Manosuthi, Weerawat, Athichathanabadi, Chatiya, Uttayamakul, Sumonmal, Phoorisri, Thanongsri, Sungkanuparph, Somnuek

    I whakaputaina 2007
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Durability of Stavudine, Lamivudine and Nevirapine among Advanced HIV-1 Infected Patients with/without Prior Co-administration of Rifampicin: A 144-week Prospective Study

    Durability of Stavudine, Lamivudine and Nevirapine among Advanced HIV-1 Infected Patients with/without Prior Co-administration of Rifampicin: A 144-week Prospective Study mā Manosuthi, Weerawat, Tantanathip, Preecha, Prasithisirikul, Wisit, Likanonsakul, Sirirat, Sungkanuparph, Somnuek

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure

    Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure mā Manosuthi, Weerawat, Thongyen, Supeda, Nilkamhang, Samruay, Manosuthi, Sukanya, Sungkanuparph, Somnuek

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    CYP2B6 18492T→C Polymorphism Compromises Efavirenz Concentration in Coinfected HIV and Tuberculosis Patients Carrying CYP2B6 Haplotype *1/*1

    CYP2B6 18492T→C Polymorphism Compromises Efavirenz Concentration in Coinfected HIV and Tuberculosis Patients Carrying CYP2B6 Haplotype *1/*1 mā Manosuthi, Weerawat, Sukasem, Chonlaphat, Thongyen, Supeda, Nilkamhang, Samruay, Manosuthi, Sukanya, Sungkanuparph, Somnuek

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Effect of nutritional counseling on low-density lipoprotein (LDL) cholesterol among Thai HIV-infected adults receiving antiretroviral therapy

    Effect of nutritional counseling on low-density lipoprotein (LDL) cholesterol among Thai HIV-infected adults receiving antiretroviral therapy mā Chotivichien, Saipin, Arab, Lenore, Prasithsirikul, Wisit, Manosuthi, Weerawat, Sinawat, Sangsom, Detels, Roger

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study

    Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infect... mā Manosuthi, Weerawat, Sungkanuparph, Somnuek, Tansuphaswadikul, Somsit, Prasithsirikul, Wisit, Athichathanabadi, Chatiya, Likanonsakul, Sirirat, Chaovavanich, Achara

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Association Between the Phenotype and Genotype of Isoniazid Resistance Among Mycobacterium tuberculosis Isolates in Thailand

    Association Between the Phenotype and Genotype of Isoniazid Resistance Among Mycobacterium tuberculosis Isolates in Thailand mā Charoenpak, Ratchanu, Santimaleeworagun, Wichai, Suwanpimolkul, Gompol, Manosuthi, Weerawat, Kongsanan, Paweena, Petsong, Suthidee, Puttilerpong, Chankit

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Optimized and Non-Optimized Personal Protective Equipment Use during the COVID-19 Pandemic in Thailand: A National Cross-Sectional Survey in a Resource-Limited Setting

    Optimized and Non-Optimized Personal Protective Equipment Use during the COVID-19 Pandemic in Thailand: A National Cross-Sectional Survey in a Resource-Limited Setting mā Moolasart, Visal, Manosuthi, Weerawat, Thienthong, Varaporn, Jaemsak, Uajai, Kongdejsakda, Winnada, Pantool, Pimonamorn, Chottanapund, Suthat

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Etiology, Clinical Course, and Outcomes of Pneumonia in the Elderly: A Retrospective and Prospective Cohort Study in Thailand

    Etiology, Clinical Course, and Outcomes of Pneumonia in the Elderly: A Retrospective and Prospective Cohort Study in Thailand mā Osman, Mayada, Manosuthi, Weerawat, Kaewkungwal, Jaranit, Silachamroon, Udomsak, Mansanguan, Chayasin, Kamolratanakul, Supitcha, Pitisuttithum, Punnee

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Patients Infected with HIV Type 1 Subtype CRF01_AE and Failing First-Line Nevirapine- and Efavirenz-Based Regimens Demonstrate Considerable Cross-Resistance to Etravirine

    Patients Infected with HIV Type 1 Subtype CRF01_AE and Failing First-Line Nevirapine- and Efavirenz-Based Regimens Demonstrate Considerable Cross-Resistance to Etravirine mā Manosuthi, Weerawat, Butler, David M., Chantratita, Wasun, Sukasem, Chonlaphat, Richman, Douglas D., Smith, Davey M.

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure

    Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure mā Manosuthi, Weerawat, Kiertiburanakul, Sasisopin, Amornnimit, Wannarat, Prasithsirikul, Wisit, Thongyen, Supeda, Nilkamhang, Samruay, Ruxrungtham, Kiat, Sungkanuparph, Somnuek

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Impact of Pharmacogenetic Markers of CYP2B6, Clinical Factors, and Drug-Drug Interaction on Efavirenz Concentrations in HIV/Tuberculosis-Coinfected Patients

    Impact of Pharmacogenetic Markers of CYP2B6, Clinical Factors, and Drug-Drug Interaction on Efavirenz Concentrations in HIV/Tuberculosis-Coinfected Patients mā Manosuthi, Weerawat, Sukasem, Chonlaphat, Lueangniyomkul, Aroon, Mankatitham, Wiroj, Thongyen, Supeda, Nilkamhang, Samruay, Manosuthi, Sukanya, Sungkanuparph, Somnuek

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults

    Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults mā Uttayamakul, Sumonmal, Likanonsakul, Sirirat, Manosuthi, Weerawat, Wichukchinda, Nuanjun, Kalambaheti, Thareerat, Nakayama, Emi E, Shioda, Tatsuo, Khusmith, Srisin

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Text
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: